Mineralys presents lorundrostat HF biomarker data at ENDO 2026
Mineralys Therapeutics has presented late-breaking proteomic data suggesting its investigational aldosterone synthase inhibitor, lorundrostat, may reduce biological markers associated with heart failure risk. The post hoc analysis, drawn from more than 1,000 participants across the Phase 3 Launch-HTN and Phase 2b Advance-HTN trials, was shown at the Endocrine Society's ENDO 2026 annual meeting in Chicago on 14 June.
The analysis profiled circulating protein biomarkers at baseline and after 12 weeks of treatment. Lorundrostat was associated with statistically significant reductions in six of eleven candidate causal risk biomarkers of incident heart failure identified in a recent large-scale proteomics study, among them NT-proBNP, a widely used clinical marker of cardiac stress. The data also showed coordinated decreases in fibrosis-related proteins alongside increases in markers of haemostasis and protease inhibitor activity, a pattern the company says points to a broad, consistent effect on disease pathways rather than isolated biomarker shifts.
Target engagement and biological rationale
Confirming target engagement, the analysis found lorundrostat treatment produced significant increases in renin and decreases in angiotensinogen, consistent with inhibition of the renin-angiotensin-aldosterone system (RAAS). Aldosterone's role in driving cardiac fibrosis and fluid retention is well documented, and the RAAS pathway is already a cornerstone of existing heart failure pharmacology through angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and mineralocorticoid receptor antagonists such as spironolactone and eplerenone.
Chief executive Jon Congleton said people with uncontrolled hypertension faced particular risk of heart failure and that "these findings suggest that lorundrostat may act on the biological processes that contribute to heart failure, supporting further evaluation of its therapeutic potential in this setting."
It is important to note that this is a post hoc, hypothesis-generating analysis, not a prospectively powered trial in heart failure. Biomarker changes do not directly confirm clinical benefit, and regulators will require dedicated outcome data before any heart failure label could be considered.
Regulatory position and competitive landscape
Lorundrostat is currently under FDA review for uncontrolled and resistant hypertension, with a PDUFA target action date of 22 December 2026. If approved, Mineralys would enter a crowded but evolving antihypertensive market. The aldosterone synthase inhibitor class has attracted growing attention: AstraZeneca's baxdrostat is in late-stage development for resistant hypertension, and the broader RAAS field continues to see investment as the limitations of existing agents in achieving blood pressure targets become clearer.
The ENDO 2026 presentation is positioned as supporting evidence for lorundrostat's mechanism beyond blood pressure lowering, a strategy that could differentiate the compound in a future heart failure or cardiorenal indication. However, investors and clinicians will rightly look for a prospectively designed heart failure outcomes trial before attributing meaningful clinical weight to these proteomic signals. Mineralys has not yet announced such a study.
With fewer than half of hypertensive patients reaching their blood pressure goals on current therapies, and dysregulated aldosterone implicated in roughly 30 per cent of hypertension cases, the commercial rationale for a selective aldosterone synthase inhibitor remains compelling. The December PDUFA date represents the company's most proximate catalyst.